ClinicalTrials.gg
RecruitingNCT07365696Updated Jan 26, 2026

Fatigue and Cognitive Dysfunction Due to Synaptopathy or Graft Versus Host (GVH) Disease in the Brain.

An observational study in Fatigue, Graft Vs Host Disease and Cognitive Dysfunction, sponsored by Karolinska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Karolinska University Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Fatigue with a site in Sweden — 14 open to participants now, 15 under way, none of them phase 3. Fatigue · Sweden.

Planned enrollment
13th of 15
30 · median 100
Started
2023
with 3 others
Observational
15 of 43
5 open now
Primary completion
2027-12
later than 10 of 14 live
Registered
29th of 43
by date
Lead sponsor
2 of 43
Karolinska University Hospital

Among the 43 studies in Fatigue with a site in Sweden, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2023, is one of 15 observational ones, reaches primary completion later than 10 of the 14 other live ones, and was the 29th registered.

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

Browse Fatigue studies →

Open to participants now

14 of the 43 studies in Fatigue with a site in Sweden are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Fatigue with a site in Sweden, or all of them as a file.
02

Study summary

Patients undergoing allogenic stem cell transplantation are regularly followed up in the outpatient clinic at Karolinska University Hospital. Here, patients are offered participation the fatigue study measuring both fatigue and cognitive impairment systematically by international standard. Meanwhile liquor samples and advanced PET imaging techniques are available for these patients as part of a research project allowing extensive immunological and radio-morphological studies.

03

Conditions studied

  • Fatigue
  • Graft Vs Host Disease
  • Cognitive Dysfunction
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients undergone allogeneic stemcell transplantation

Eligibility criteria

Inclusion Criteria: PET images available retrospectively

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with fatigue and cognitive dysfunction

    Radiation: PET investigation

  • Patients without fatigue and cognitive dysfunction

    Radiation: PET investigation

Interventions

  • RadiationPET investigation

    Trial subjects will undergo two advanced PET investigations

06

What researchers measure

Primary outcomes

  1. To investigate the role of inflammation on synaptic density and glial cell activation as the cause of mental fatigue and cognitive dysfunction in survivors after alloSCT.

    Analysis of PET imaging (both descriptive and radiokinetical) in combination with biological markers for neuroinflammation.

    Time frame: 2024-2027

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2027, 49 months after the start.

Of 156 non-industry observational studies under Fatigue, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 45. This study's planned 49 months is above that.

Counting every sponsor, half of 166 studies reached it within 24 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Jan 26, 2026
StartActual
Nov 28, 2023
Primary completionEst.
Dec 28, 2027
CompletionEst.
Dec 28, 2028
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07365696
Responsible party
Ksenia Boriskina (MD, Karolinska University Hospital) — Principal investigator
First posted
Jan 26, 2026
Start date
Nov 28, 2023
Primary completion
Dec 28, 2027 (estimated)
Completion
Dec 28, 2028 (estimated)
Last update
Jan 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion